National Medical Care Gelecekteki Büyüme
Future kriter kontrolleri 2/6
National Medical Care kazanç ve gelirin sırasıyla yıllık 11.5% ve 12.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 19.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
11.5%
Kazanç büyüme oranı
11.1%
EPS büyüme oranı
Healthcare kazanç büyümesi | 15.0% |
Gelir büyüme oranı | 12.6% |
Gelecekteki özkaynak getirisi | 19.7% |
Analist kapsamı | Good |
Son güncelleme | 03 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
National Medical Care's (TADAWUL:4005) Solid Earnings May Rest On Weak Foundations
Oct 29National Medical Care (TADAWUL:4005) Shareholders Will Want The ROCE Trajectory To Continue
Sep 25Analysts Are Updating Their National Medical Care Company (TADAWUL:4005) Estimates After Its Second-Quarter Results
Aug 06Getting In Cheap On National Medical Care Company (TADAWUL:4005) Is Unlikely
Jul 26National Medical Care Company's (TADAWUL:4005) Shares May Have Run Too Fast Too Soon
Apr 05We Think National Medical Care's (TADAWUL:4005) Robust Earnings Are Conservative
Mar 14National Medical Care (TADAWUL:4005) Is Very Good At Capital Allocation
Mar 13Some Confidence Is Lacking In National Medical Care Company's (TADAWUL:4005) P/E
Dec 27Returns On Capital Are Showing Encouraging Signs At National Medical Care (TADAWUL:4005)
Dec 05We Like These Underlying Return On Capital Trends At National Medical Care (TADAWUL:4005)
Aug 07Is National Medical Care Company (TADAWUL:4005) Worth ر.س107 Based On Its Intrinsic Value?
May 29Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
May 08Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
Dec 19A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Oct 19National Medical Care (TADAWUL:4005) Is Doing The Right Things To Multiply Its Share Price
Aug 15National Medical Care's (TADAWUL:4005) Returns On Capital Are Heading Higher
May 13Earnings Update: National Medical Care Company (TADAWUL:4005) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 03A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Feb 10Returns At National Medical Care (TADAWUL:4005) Appear To Be Weighed Down
Nov 10Returns On Capital At National Medical Care (TADAWUL:4005) Have Hit The Brakes
Jul 02Estimating The Intrinsic Value Of National Medical Care Company (TADAWUL:4005)
Apr 14Is National Medical Care Company (TADAWUL:4005) A Risky Dividend Stock?
Mar 25Will National Medical Care (TADAWUL:4005) Multiply In Value Going Forward?
Feb 23Update: National Medical Care (TADAWUL:4005) Stock Gained 25% In The Last Five Years
Feb 09National Medical Care Company's (TADAWUL:4005) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?
Jan 27Calculating The Fair Value Of National Medical Care Company (TADAWUL:4005)
Jan 14Is National Medical Care Company's (TADAWUL:4005) 3.8% Dividend Sustainable?
Dec 25Does National Medical Care's (TADAWUL:4005) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 10What Kind Of Shareholders Hold The Majority In National Medical Care Company's (TADAWUL:4005) Shares?
Nov 24Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 1,733 | 387 | 316 | 457 | 6 |
12/31/2025 | 1,556 | 342 | 189 | 386 | 6 |
12/31/2024 | 1,279 | 298 | -19 | 227 | 5 |
9/30/2024 | 1,221 | 274 | -127 | -72 | N/A |
6/30/2024 | 1,171 | 288 | -134 | 88 | N/A |
3/31/2024 | 1,119 | 266 | 212 | 423 | N/A |
12/31/2023 | 1,082 | 241 | 412 | 467 | N/A |
9/30/2023 | 1,034 | 233 | 825 | 690 | N/A |
6/30/2023 | 997 | 202 | 670 | 531 | N/A |
3/31/2023 | 968 | 196 | 349 | 386 | N/A |
12/31/2022 | 918 | 170 | 185 | 217 | N/A |
9/30/2022 | 882 | 151 | -162 | 52 | N/A |
6/30/2022 | 857 | 142 | -126 | 86 | N/A |
3/31/2022 | 843 | 131 | 8 | 45 | N/A |
12/31/2021 | 845 | 136 | 56 | 94 | N/A |
9/30/2021 | 844 | 122 | 58 | 94 | N/A |
6/30/2021 | 845 | 105 | 15 | 49 | N/A |
3/31/2021 | 828 | 100 | 17 | 40 | N/A |
12/31/2020 | 809 | 97 | 88 | 107 | N/A |
9/30/2020 | 780 | 95 | 187 | 198 | N/A |
6/30/2020 | 740 | 95 | 216 | 225 | N/A |
3/31/2020 | 724 | 83 | 155 | 162 | N/A |
12/31/2019 | 708 | 80 | 152 | 162 | N/A |
9/30/2019 | 705 | 65 | 236 | 246 | N/A |
6/30/2019 | 707 | 60 | 245 | 259 | N/A |
3/31/2019 | 737 | 67 | 188 | 206 | N/A |
12/31/2018 | 764 | 62 | 299 | 318 | N/A |
9/30/2018 | 810 | 81 | 199 | 231 | N/A |
6/30/2018 | 842 | 96 | N/A | 236 | N/A |
3/31/2018 | 859 | 95 | N/A | 279 | N/A |
12/31/2017 | 855 | 85 | N/A | 113 | N/A |
9/30/2017 | 817 | -8 | N/A | -9 | N/A |
6/30/2017 | 806 | -7 | N/A | 70 | N/A |
3/31/2017 | 849 | 33 | N/A | 72 | N/A |
12/31/2016 | 901 | 50 | N/A | 103 | N/A |
9/30/2016 | 931 | 155 | N/A | 87 | N/A |
6/30/2016 | 945 | 153 | N/A | 63 | N/A |
3/31/2016 | 913 | 136 | N/A | 77 | N/A |
12/31/2015 | 879 | 131 | N/A | 51 | N/A |
9/30/2015 | 853 | 106 | N/A | 127 | N/A |
6/30/2015 | 820 | 102 | N/A | 80 | N/A |
3/31/2015 | 772 | 91 | N/A | 38 | N/A |
12/31/2014 | 734 | 95 | N/A | 71 | N/A |
9/30/2014 | 703 | 106 | N/A | 32 | N/A |
6/30/2014 | 660 | 103 | N/A | 15 | N/A |
3/31/2014 | 623 | 94 | N/A | 75 | N/A |
12/31/2013 | 586 | 92 | N/A | 79 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 4005 'nin tahmini kazanç büyümesi (yıllık 11.5% ) tasarruf oranının ( 14.7% ) altındadır.
Kazançlar ve Piyasa: 4005 şirketinin kazançlarının (yıllık 11.5% ) SA pazarından (yıllık 6.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: 4005 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: 4005 şirketinin gelirinin (yıllık 12.6% ) SA pazarından (yıllık 1.2% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 4005 şirketinin gelirinin (yıllık 12.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 4005 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 19.7 %).